News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1โ€“36
Matches
45
Sources here
16
Companies here
1
Search results Stored financial headlines

Active search

45 matching headlines

Ticker or company: QNRXMain companies and provider mentions
Clear
Latest

Investing.com Market update

Quoin Pharmaceuticals CFO Lawlor buys $49,990 in company stock

Quoin Pharmaceuticals CFO Sally Bridget Lawlor recently purchased 10,244 American Depositary Shares (ADSs) worth $49,990 at $4.88 per ADS as part of a private placement. This acquisition increased her direct beneficial ownership to 10,684 ADSs, and she also acquired warrants to buy an additional 5,122 ADSs. The company's stock has since rallied, and Quoin Pharmaceuticals is also expanding โ€ฆ

Main company ๐Ÿ‡บ๐Ÿ‡ธ United States
Read at Investing.com
Sharemaestro market context Price above Trend Line 52 weeks -4.5% ยท Next-week setup negative 38.8% QNRX stored weekly price path from 12 Sep 2025 to 4 Sep 2026
Just inNext headlines
Investing.com Earnings Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Quoin Pharmaceuticals CEO Michael Myers buys $99,991 ADSs

Michael Myers, CEO of Quoin Pharmaceuticals, recently purchased 20,490 American Depositary Shares (ADSs) for $99,991, at $4.88 per ADS. The stock has since risen 26% to $6.51. This transaction was part of a private placement and included warrants, while the company also made strategic โ€ฆ

QNRX main company
Sharemaestro market context Price above Trend Line 52 weeks -4.5% ยท Next-week setup negative 38.8% QNRX stored weekly price path from 12 Sep 2025 to 4 Sep 2026
Investing.com Market update Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Quoin Pharmaceuticals director Culverwell buys $29,992 in ADSs

Quoin Pharmaceuticals director Anthony James Culverwell purchased 6,146 American Depositary Shares (ADSs) for $29,992 on August 31, 2026, as part of a private placement. The stock has since gained over 33%, and Culverwell now holds 40,364 ADSs and 3,073 ordinary warrants. This transaction follows โ€ฆ

QNRX main company
Sharemaestro market context Price above Trend Line 52 weeks -4.5% ยท Next-week setup negative 38.8% QNRX stored weekly price path from 12 Sep 2025 to 4 Sep 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Investing.com Market update Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Quoin Pharmaceuticals raises $30.8M in private placement

Quoin Pharmaceuticals (NASDAQ:QNRX) has successfully raised $30.8 million in an initial private placement, part of a larger agreement that could yield up to $50.0 million. This financing round involved healthcare-focused institutional investors, as well as members of the company's management and board. The funds โ€ฆ

QNRX main company
Sharemaestro market context Price above Trend Line 52 weeks -4.5% ยท Next-week setup negative 38.8% QNRX stored weekly price path from 12 Sep 2025 to 4 Sep 2026
Zacks Small Cap Research Regulatory and legal Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

QNRX: Believe Conditional FDA Approval of Proposed Brand Name Reflects QRX003 Nearing Potential Commercialization

QNRX main company
Sharemaestro market context Price above Trend Line 52 weeks -4.5% ยท Next-week setup negative 38.8% QNRX stored weekly price path from 12 Sep 2025 to 4 Sep 2026
Moomoo Market update Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Quoin Pharmaceuticals | 8-K: Current report

This article is a current report filed by Quoin Pharmaceuticals as an 8-K document. The content of the report indicates standard corporate disclosure, likely concerning significant events required by regulatory bodies.

QNRX main company
Sharemaestro market context Price above Trend Line 52 weeks -4.5% ยท Next-week setup negative 38.8% QNRX stored weekly price path from 12 Sep 2025 to 4 Sep 2026
Stock Titan Earnings Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Quoin Pharma (NASDAQ: QNRX) lifts board pay ceiling to $250K plus options

Quoin Pharmaceuticals (NASDAQ: QNRX) shareholders approved significant changes to their non-employee director compensation program at the 2026 Annual General Meeting. The amendments raise the annual base cash retainer to a maximum of $250,000 and set an annual option award value range between $20,000 and โ€ฆ

QNRX main company
Sharemaestro market context Price above Trend Line 52 weeks -4.5% ยท Next-week setup negative 38.8% QNRX stored weekly price path from 12 Sep 2025 to 4 Sep 2026
TradingView Market update Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Price to book forward of Quoin Pharmaceuticals, Ltd. โ€“ NASDAQ:QNRX

The article displays the "Price to book forward" for Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) as provided by TradingView. It indicates that the market was closed and no trades were made at the time of publication. The content primarily focuses on financial data presentation within โ€ฆ

QNRX main company
Sharemaestro market context Price above Trend Line 52 weeks -4.5% ยท Next-week setup negative 38.8% QNRX stored weekly price path from 12 Sep 2025 to 4 Sep 2026
Moomoo Earnings Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Quoin Pharmaceuticals | 10-Q: Quarterly report

This document is a quarterly report (10-Q) filed by Quoin Pharmaceuticals. It contains financial statements and other important disclosures required by the Securities and Exchange Commission for the reporting period.

QNRX main company
Sharemaestro market context Price above Trend Line 52 weeks -4.5% ยท Next-week setup negative 38.8% QNRX stored weekly price path from 12 Sep 2025 to 4 Sep 2026
Moomoo Earnings Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Quoin Pharmaceuticals | 10-Q: Q2 2026 Earnings Report

This document is the Q2 2026 Earnings Report in 10-Q format for Quoin Pharmaceuticals. It contains the financial statements and disclosures for the second quarter of 2026, providing insights into the company's performance.

QNRX main company
Sharemaestro market context Price above Trend Line 52 weeks -4.5% ยท Next-week setup negative 38.8% QNRX stored weekly price path from 12 Sep 2025 to 4 Sep 2026
Quiver Quantitative Earnings Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Quoin Q2 Loss Hits $5.37 Million as FDA Clears Peeling Skin IND

Quoin Pharmaceuticals Ltd. (QNRX) reported a net loss of $5.37 million for the second quarter of 2026, an increase from $3.70 million in the prior year. Despite this, the company's cash position is expected to fund operations into 2027. The FDA also conditionally approved โ€ฆ

QNRX main company
Sharemaestro market context Price above Trend Line 52 weeks -4.5% ยท Next-week setup negative 38.8% QNRX stored weekly price path from 12 Sep 2025 to 4 Sep 2026
AlphaStreet Earnings Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Quoin Pharmaceuticals Releases Q2 2026 Financial Results

Quoin Pharmaceuticals (QNRX) announced its Q2 2026 financial results, reporting a diluted EPS of -$1.90, which is a significant improvement from the -$6.28 loss in Q2 2025. The company posted a net loss of $5.4 million for the quarter. Wall Street analysts currently have โ€ฆ

QNRX main company
Sharemaestro market context Price above Trend Line 52 weeks -4.5% ยท Next-week setup negative 38.8% QNRX stored weekly price path from 12 Sep 2025 to 4 Sep 2026
nasdaq.com Earnings Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Quoin Q2 Loss Widens; Gets FDA's Conditional Nod For QYLEKI Brand Name For QRX003

(RTTNews) - Quoin Pharmaceuticals Ltd. (QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, reported second-quarter 2026 results and provided a corporate update highlighting progress across its QRX003 and QRX009 platforms. Quoin is developing topical therapies for rare dermatologic conditions, โ€ฆ

QNRX main company
Sharemaestro market context Price above Trend Line 52 weeks -4.5% ยท Next-week setup negative 38.8% QNRX stored weekly price path from 12 Sep 2025 to 4 Sep 2026
Stock Titan Earnings Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

No approved treatment for Peeling Skin Syndrome as Quoin plans Phase 2/3 study

Quoin Pharmaceuticals reported key pipeline milestones and its Q2 2026 financial results. The FDA granted conditional approval for QYLEKIโ„ข as the proposed brand name for QRX003, intended for Netherton Syndrome, and cleared the first-ever IND for Peeling Skin Syndrome, enabling a Phase 2/3 study โ€ฆ

QNRX main company
Sharemaestro market context Price above Trend Line 52 weeks -4.5% ยท Next-week setup negative 38.8% QNRX stored weekly price path from 12 Sep 2025 to 4 Sep 2026
Moomoo Earnings Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Quoin Pharmaceuticals (QNRX.US) will release its earnings report before the market opens on August 14.

Quoin Pharmaceuticals (QNRX.US) is scheduled to release its earnings report on August 14. The announcement will be made before the market opens. Investors and analysts will be closely watching the report for insights into the company's financial performance.

QNRX main company
Sharemaestro market context Price above Trend Line 52 weeks -4.5% ยท Next-week setup negative 38.8% QNRX stored weekly price path from 12 Sep 2025 to 4 Sep 2026
Yahoo! Finance Canada Earnings Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced it will release its second quarter 2026 financial results and provide a corporate update before the market opens on Friday, August 14, 2026. The update will include an operational overview, recent achievements, and financial highlights for the quarter โ€ฆ

QNRX main company
Sharemaestro market context Price above Trend Line 52 weeks -4.5% ยท Next-week setup negative 38.8% QNRX stored weekly price path from 12 Sep 2025 to 4 Sep 2026
Stock Titan Earnings Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Quoin plans an operational update before markets open Aug. 14

Quoin Pharmaceuticals (NASDAQ: QNRX) announced it will provide a corporate update and release its second-quarter 2026 financial results before the U.S. market opens on Friday, August 14, 2026. The update will highlight key achievements, recent accomplishments, and financial performance for the quarter ended June โ€ฆ

QNRX main company
Sharemaestro market context Price above Trend Line 52 weeks -4.5% ยท Next-week setup negative 38.8% QNRX stored weekly price path from 12 Sep 2025 to 4 Sep 2026
TradingKey Earnings Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Quoin Pharmaceuticals Ltd (QNRX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Quoin Pharmaceuticals Ltd (QNRX), indicating a current earnings forecast score of 8.00 and an average price target of $30.00 among analysts. Based on ratings from 4 analysts, the stock receives a "Buy" trend recommendation with a significant โ€ฆ

QNRX main company
Sharemaestro market context Price above Trend Line 52 weeks -4.5% ยท Next-week setup negative 38.8% QNRX stored weekly price path from 12 Sep 2025 to 4 Sep 2026
TradingView Earnings Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Quoin Pharmaceuticals Ltd expected to post a loss of $1.61 a share - Earnings Preview

Quoin Pharmaceuticals Ltd (QNRX) is projected to report a loss of $1.61 per share, according to this earnings preview. The article, sourced from Reuters, provides an outlook on the company's upcoming financial performance.

QNRX main company
Sharemaestro market context Price above Trend Line 52 weeks -4.5% ยท Next-week setup negative 38.8% QNRX stored weekly price path from 12 Sep 2025 to 4 Sep 2026
Kalkine Balance sheet Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Quoin Pharmaceuticals (NASDAQ:QNRX) gets FDA clearance for Phase 2 study in ultra-rare peeling skin syndrome

Quoin Pharmaceuticals (NASDAQ:QNRX) received FDA clearance for a Phase 2 study of QRX003 in Peeling Skin Syndrome, expanding its lead asset beyond its initial target, Netherton syndrome. This clearance, announced on July 9, 2026, marks a significant regulatory milestone but comes amidst Quoin's disclosed โ€ฆ

QNRX main company
Sharemaestro market context Price above Trend Line 52 weeks -4.5% ยท Next-week setup negative 38.8% QNRX stored weekly price path from 12 Sep 2025 to 4 Sep 2026
TradingKey Earnings Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

QNRX|Quoin Pharmaceuticals Ltd|Price:4.380|Chg%:+0.180

This article provides current market data, analysis, and key insights for Quoin Pharmaceuticals Ltd (QNRX). It highlights the company's strong fundamentals, high growth potential, and "Buy" rating from analysts with significant upside potential despite recent stock market performance. The article also details Quoin Pharmaceuticals' โ€ฆ

QNRX main company
Sharemaestro market context Price above Trend Line 52 weeks -4.5% ยท Next-week setup negative 38.8% QNRX stored weekly price path from 12 Sep 2025 to 4 Sep 2026
TradingKey Market update Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Quoin Pharmaceuticals Ltd (QNRX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Quoin Pharmaceuticals Ltd (QNRX), identifying its major individual and institutional holders. It provides a breakdown of share proportions by shareholder type and tracks changes in institutional holdings over several quarters. Key information includes top holders like Ikarian โ€ฆ

QNRX main company
Sharemaestro market context Price above Trend Line 52 weeks -4.5% ยท Next-week setup negative 38.8% QNRX stored weekly price path from 12 Sep 2025 to 4 Sep 2026
TradingKey Capital return Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Quoin Pharmaceuticals Ltd (QNRX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for Quoin Pharmaceuticals Ltd (QNRX). It notes that no dividends have been distributed over the past five years and lists several merger-related stock splits with their respective ex-dividend dates, types, and ratios from 2022 to โ€ฆ

QNRX main company
Sharemaestro market context Price above Trend Line 52 weeks -4.5% ยท Next-week setup negative 38.8% QNRX stored weekly price path from 12 Sep 2025 to 4 Sep 2026
TradingKey Market update Main company ๐Ÿ‡บ๐Ÿ‡ธ United States

Quoin Pharmaceuticals Ltd (QNRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Quoin Pharmaceuticals Ltd (QNRX), covering its current price momentum, support and resistance levels, and various technical indicators and moving averages. The stock currently has a price momentum score of 4.14 within the Biotechnology & Medical Research industry, โ€ฆ

QNRX main company
Sharemaestro market context Price above Trend Line 52 weeks -4.5% ยท Next-week setup negative 38.8% QNRX stored weekly price path from 12 Sep 2025 to 4 Sep 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context